BioSpace News Archive

The company was assessing mavrilimumab as a potential therapeutic for COVID-19-related acute respiratory syndrome.

Collegium reached a $2.75 million agreement with a law firm representing 27 U.S. cities, counties and subdivisions related to the opioid crisis and the company’s sale of Xtampza.

The decision to allow the release of Adbry follows positive results from the Phase III ECZTRA trials, which covered almost 2,000 patients living with moderate to severe atopic dermatitis.

BridgeBio Pharma reported topline data from Part A (Month 12) of its Phase III study of acoramidis for symptomatic transthyretin amyloid cardiomyopathy. The drug failed the study arm.

Nykode Therapeutics AS announced the first subject has been dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate in its VB-D-01 Phase 1/2 trial.

RELIEF THERAPEUTICS Holding SA reported that the Swiss Patent Office IPI has announced that it expects to conclude the patent application procedure by January 24, 2022 and to issue the patent entitled, “Vasoactive Intestinal Peptide for the Use in the Treatment of Drug-induced Pneumonitis,” as applied for by Relief’s subsidiary, AdVita Lifescience GmbH, in 2020.

LEO Pharma Inc. announced that the U.S. Food and Drug Administration has approved Adbry™ for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Kiniksa Pharmaceuticals, Ltd. today announced that the Phase 3 portion of the Phase 2/3 trial of mavrilimumab in COVID-19-related acute respiratory syndrome (ARDS) did not meet the primary efficacy endpoint.

The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, which showcased the impact of the COVID-19 pandemic on aesthetic plastic surgery procedures.

Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday, January 12, 2022, at 5:15 p.m. ET.